CA2505479A1 - Interactions moleculaires dans des neurones - Google Patents
Interactions moleculaires dans des neurones Download PDFInfo
- Publication number
- CA2505479A1 CA2505479A1 CA002505479A CA2505479A CA2505479A1 CA 2505479 A1 CA2505479 A1 CA 2505479A1 CA 002505479 A CA002505479 A CA 002505479A CA 2505479 A CA2505479 A CA 2505479A CA 2505479 A1 CA2505479 A1 CA 2505479A1
- Authority
- CA
- Canada
- Prior art keywords
- pdz
- polypeptide
- protein
- binding
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des inhibiteurs perturbant la liaison entre une protéine PDZ et des ligands associés, notamment des récepteurs de N-méthyle-D-aspartate, impliqués dans des troubles neurologiques variés. L'invention concerne des compositions pharmaceutiques contenant ces inhibiteurs, et leur utilisation dans le traitement de maladies neurologiques, notamment l'accident vasculaire cérébral et l'ischémie. L'invention concerne des méthodes de criblage permettant d'identifier des inhibiteurs supplémentaires d'interactions de ligands protéiniques spécifiques avec des protéines PDZ.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42621302P | 2002-11-14 | 2002-11-14 | |
US42621202P | 2002-11-14 | 2002-11-14 | |
US60/426,213 | 2002-11-14 | ||
US60/426,212 | 2002-11-14 | ||
PCT/US2003/036698 WO2004045535A2 (fr) | 2002-11-14 | 2003-11-14 | Interactions moleculaires dans des neurones |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2505479A1 true CA2505479A1 (fr) | 2004-06-03 |
Family
ID=32329101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002505479A Abandoned CA2505479A1 (fr) | 2002-11-14 | 2003-11-14 | Interactions moleculaires dans des neurones |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1578365A4 (fr) |
CA (1) | CA2505479A1 (fr) |
WO (1) | WO2004045535A2 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6942981B1 (en) | 1999-05-14 | 2005-09-13 | Arbor Vita Corporation | Method of determining interactions with PDZ-domain polypeptides |
US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
US7858322B2 (en) | 2003-12-23 | 2010-12-28 | Nono, Inc. | Method of determining inhibition of binding to TRPM7 protein |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
CA2613012A1 (fr) | 2005-06-23 | 2007-01-04 | Arbor Vita Corporation | Procedes et compositions de modulation de la cox |
WO2007031098A1 (fr) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Inhibiteurs peptidiques permeables aux cellules de la voie de transduction de signal jnk |
US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
EP1790664A1 (fr) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Anticorps monoclonaux contre claudin-18 pour le traitement du cancer |
US8633160B2 (en) * | 2005-12-30 | 2014-01-21 | Nono Inc. | Small molecule inhibitors of PDZ interactions |
JP5746468B2 (ja) * | 2006-07-11 | 2015-07-08 | ノノ インコーポレイテッド | 発熱を伴う脳卒中を処置する方法および組成物 |
EP1884521A1 (fr) * | 2006-07-31 | 2008-02-06 | Xigen S.A. | Peptide de fusion pour inhiber l'interaction du récepteur neuronal NMDA (NMDAR) avec les protéines interagissant avec le récepteur NMDA |
US8008253B2 (en) * | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
WO2009143865A1 (fr) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Utilisation d'inhibiteurs peptidiques des voies de traduction du signal jnk perméables aux cellules pour le traitement de diverses maladies |
WO2009143864A1 (fr) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Utilisation d'inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de maladies digestives inflammatoires chroniques ou non chroniques |
WO2010072228A1 (fr) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Nouvelles constructions transporteuses et molécules conjuguées cargo/transporteuses |
CA2765171C (fr) * | 2009-06-10 | 2018-10-02 | Nono Inc. | Co-administration d'un agent lie a un peptide d'internalisation avec un anti-inflammatoire |
BRPI1010718A2 (pt) * | 2009-06-10 | 2016-03-15 | Nono Inc | sistemas modelo e regimes de tratamento para tratar doença neurológica. |
WO2011160653A1 (fr) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Nouvelles molécules inhibant jnk |
WO2012048721A1 (fr) | 2010-10-14 | 2012-04-19 | Xigen S.A. | Utilisation d'inhibiteurs peptidiques, aptes à pénétrer dans les cellules, de la voie de transduction du signal jnk pour le traitement de maladies oculaires inflammatoires chroniques ou non-chroniques |
EP2581384A1 (fr) * | 2011-10-11 | 2013-04-17 | Institut Pasteur | Produits utiles pour le traitement des tumeurs malignes du système nerveux humain |
WO2013091670A1 (fr) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Nouvelles molécules inhibitrices de jnk pour le traitement de diverses maladies |
WO2013167153A1 (fr) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Anticorps utiles dans le diagnostic du cancer |
WO2014206427A1 (fr) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | Nouvelle utilisation d'inhibiteurs de peptides à perméabilité cellulaire dans la voie de transduction du signal jnk pour le traitement de diverses maladies |
WO2015197097A1 (fr) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies |
CN106554386A (zh) * | 2015-09-25 | 2017-04-05 | 广州恒上医药技术有限公司 | 人***瘤病毒的表位肽及其应用 |
EP3723781A4 (fr) | 2017-12-13 | 2021-07-21 | The Research Foundation for the State University of New York | Peptides et autres agents pour traiter la douleur et augmenter la sensibilité à la douleur |
CN114807142B (zh) * | 2022-05-26 | 2024-03-29 | 源生生物科技(青岛)有限责任公司 | 一种环状RNA-circ-Magi1及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003014303A2 (fr) * | 2001-08-03 | 2003-02-20 | Arbor Vita Corporation | Interactions moleculaires dans les cellules |
CA2273622C (fr) * | 1999-06-02 | 2012-03-20 | Michael Tymianski | Inhibition de la signalisation induite par le recepteur nmda dans le but de reduire les lesions neuronales |
AU2001277986A1 (en) * | 2000-07-25 | 2002-02-05 | Axcell Biosciences Corporation | Identification and isolation of novel polypeptides having pdz domains and methods of using same |
EP1351980B1 (fr) * | 2001-01-18 | 2014-12-31 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides destines a l'activation et a l'inhibition de of delta pkc |
JP3536039B2 (ja) * | 2001-05-08 | 2004-06-07 | 独立行政法人 科学技術振興機構 | Htlv−i腫瘍に対する抗腫瘍抗原又はその抗原エピトープ |
-
2003
- 2003-11-14 WO PCT/US2003/036698 patent/WO2004045535A2/fr not_active Application Discontinuation
- 2003-11-14 EP EP03768964A patent/EP1578365A4/fr not_active Withdrawn
- 2003-11-14 CA CA002505479A patent/CA2505479A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1578365A2 (fr) | 2005-09-28 |
EP1578365A4 (fr) | 2009-09-23 |
WO2004045535A3 (fr) | 2006-07-13 |
WO2004045535A2 (fr) | 2004-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110039758A1 (en) | Molecular Interactions in Neurons | |
CA2505479A1 (fr) | Interactions moleculaires dans des neurones | |
US7858322B2 (en) | Method of determining inhibition of binding to TRPM7 protein | |
US20090075377A1 (en) | Molecular interactions in cells | |
CA2457424A1 (fr) | Interactions moleculaires dans les cellules | |
US7972774B2 (en) | Methods of diagnosing cervical cancer | |
US20100120700A1 (en) | Methods and compositions for treating cervical cancer | |
US20050019841A1 (en) | Modulation of signaling pathways | |
US7514224B2 (en) | Arrays of PDZ domain polypeptides | |
AU2008258186A1 (en) | Methods of diagnosing cervical cancer | |
US20120093873A1 (en) | Molecular Interactions in Hematopoietic Cells | |
US20050282743A1 (en) | Molecular interactions in cells | |
JP2009503439A (ja) | ウイルス感染および細菌感染の診断および処置のための方法および組成物 | |
US7919584B1 (en) | Methods and compositions for diagnosis and treatment of asthma | |
AU2003291558B2 (en) | Molecular interactions in neurons | |
WO2002031512A2 (fr) | Interactions moleculaires dans des cellules hematopoietiques | |
EP1599214A2 (fr) | Methodes et compositions destinees a traiter le cancer du col uterin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |